Seres Therapeutics, Inc. (NASDAQ:MCRB) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a research report issued on Friday.

Several other research firms also recently commented on MCRB. Zacks Investment Research downgraded shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 8th. ValuEngine upgraded shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Canaccord Genuity set a $20.00 price target on shares of Seres Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 3rd. HC Wainwright restated a “buy” rating and issued a $19.00 price target (up from $15.00) on shares of Seres Therapeutics in a research note on Friday, August 4th. Finally, Cantor Fitzgerald set a $16.00 price target on shares of Seres Therapeutics and gave the company a “buy” rating in a research note on Thursday, May 4th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $17.00.

Shares of Seres Therapeutics (NASDAQ MCRB) opened at 13.77 on Friday. Seres Therapeutics has a 12 month low of $8.85 and a 12 month high of $15.09. The firm’s market capitalization is $557.85 million. The stock’s 50 day moving average is $12.55 and its 200 day moving average is $10.69.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by $0.10. Seres Therapeutics had a negative net margin of 441.38% and a negative return on equity of 80.21%. The business had revenue of $3 million during the quarter, compared to analyst estimates of $3 million. During the same quarter last year, the company posted ($0.70) earnings per share. The company’s revenue was up .0% on a year-over-year basis. Equities research analysts forecast that Seres Therapeutics will post ($2.48) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/08/13/seres-therapeutics-inc-nasdaqmcrb-downgraded-by-bidaskclub-to-hold.html.

A number of large investors have recently made changes to their positions in MCRB. Parametric Portfolio Associates LLC increased its stake in shares of Seres Therapeutics by 1.3% in the first quarter. Parametric Portfolio Associates LLC now owns 21,335 shares of the biotechnology company’s stock worth $240,000 after buying an additional 279 shares during the last quarter. Teachers Advisors LLC increased its stake in shares of Seres Therapeutics by 1.2% in the second quarter. Teachers Advisors LLC now owns 38,758 shares of the biotechnology company’s stock worth $438,000 after buying an additional 450 shares during the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of Seres Therapeutics by 0.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 91,543 shares of the biotechnology company’s stock worth $1,035,000 after buying an additional 494 shares during the last quarter. American International Group Inc. increased its stake in shares of Seres Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 10,977 shares of the biotechnology company’s stock worth $124,000 after buying an additional 727 shares during the last quarter. Finally, Alps Advisors Inc. increased its stake in shares of Seres Therapeutics by 5.0% in the second quarter. Alps Advisors Inc. now owns 36,457 shares of the biotechnology company’s stock worth $412,000 after buying an additional 1,739 shares during the last quarter. Hedge funds and other institutional investors own 75.31% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.